VRDN logo

VIRIDIAN THERAPEUTICS INC

VRDNNASDAQ
🏆 #1888 by market capUS Equity
$20.01▼ $0.55 (−2.77%)
Live
🔔
Track VRDN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.8%
7d▼ 9.6%
14d▼ 8.4%
30d▼ 13.3%
ytd▼ 35.7%
1y▼ 7.4%
🏦Market Cap
$2.27B
Small Cap
📈Revenue Growth (YoY)
+23359.9%
High Growth
📊Gross Margin
99.5%
High
💵FCF Margin
-471.0%
Thin
⚖️P/S Ratio
32.9x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$19.70 – $20.20
52-Week Range
$13.18 – $34.29
Volume
$2.73B
Avg Volume
$2.39B
Shares Outstanding
113.3M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$71M
Last Q Revenue
$284,000
P/E Ratio
-5.8
P/S Ratio
32.9x
EPS (TTM)
$-3.59
Dividend Yield
0.00%
Dilution (1yr)
+5.9%

Why Investors Own VRDN

  • ✓High-growth profile — revenue up -0.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 39% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VRDN logo

VIRIDIAN THERAPEUTICS INC

VRDN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$71M▲ +23359.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$363M▲ +21.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$277M▲ +18.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
84.8M▲ +5.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$162M▲ +$83M YoY
StockOtter · stockotter.space

About VIRIDIAN THERAPEUTICS INC

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$20.44
▲ +2.1% Upside
High Target$22.12
Low Target$15.84
Based on 11 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

VIRIDIAN THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift VRDN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

VIRIDIAN THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.